Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer

Despite spontaneous or vaccination-induced immune responses, pancreatic cancer remains one of the most deadly immunotherapy-resistant malignancies. We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity. An au...

Full description

Saved in:
Bibliographic Details
Main Authors: Heller, Anette (Author) , Zörnig, Inka (Author) , Müller, T. (Author) , Giorgadze, K. (Author) , Frei, Claudia (Author) , Giese, Thomas (Author) , Bergmann, Frank (Author) , Schmidt, Jan (Author) , Werner, Jens (Author) , Büchler, Markus W. (Author) , Jäger, Dirk (Author) , Giese, Nathalia (Author)
Format: Article (Journal)
Language:English
Published: 01 June 2010
In: Cancer immunology immunotherapy
Year: 2010, Volume: 59, Issue: 9, Pages: 1389-1400
ISSN:1432-0851
DOI:10.1007/s00262-010-0870-9
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00262-010-0870-9
Get full text
Author Notes:A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M.W. Buchler, D. Jaeger, N.A. Giese

MARC

LEADER 00000caa a2200000 c 4500
001 1843116804
003 DE-627
005 20240327080243.0
007 cr uuu---uuuuu
008 230419s2010 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00262-010-0870-9  |2 doi 
035 |a (DE-627)1843116804 
035 |a (DE-599)KXP1843116804 
035 |a (OCoLC)1389806185 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Heller, Anette  |e VerfasserIn  |0 (DE-588)1033180734  |0 (DE-627)740119443  |0 (DE-576)380768488  |4 aut 
245 1 0 |a Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer  |c A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M.W. Buchler, D. Jaeger, N.A. Giese 
264 1 |c 01 June 2010 
300 |b Illustrationen 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 19.04.2023 
520 |a Despite spontaneous or vaccination-induced immune responses, pancreatic cancer remains one of the most deadly immunotherapy-resistant malignancies. We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity. An autologous SEREX-based screening of a cDNA library constructed from a pancreatic T3N0M0/GIII specimen belonging to a long-term survivor (36 months) revealed 18 immunogenic pTAA. RT-PCR analysis displayed broad distribution of the identified antigens among normal human tissues. PNLIPRP2 and MIA demonstrated the most distinct pancreatic cancer-specific patterns. ELISA-based screening of sera for corresponding autoantibodies revealed that although significantly increased, the immunogenicity of these molecules was not a common feature in pancreatic cancer. QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies. Analyses of MIA—known to be preferentially expressed in malignant cells—surprisingly revealed an inverse correlation between intratumoral gene expression and the emergence of autoantibodies. MIAhigh patients were autoantibody-negative and had shorter median survival when compared with autoantibody-positive MIAlow patients (12 vs. 34 months). The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects. Applying the concept of cancer immunoediting to interpret relationships between gene expression, antitumor immune responses, and clinical outcome might better discriminate between past and ongoing immune responses, consequently enabling prognostic stratification of patients and individual adjustment of immunotherapy. 
650 4 |a Antibody 
650 4 |a Immunoediting 
650 4 |a MIA 
650 4 |a Pancreatic cancer 
650 4 |a PNLIPRP2 
650 4 |a SEREX 
700 1 |a Zörnig, Inka  |e VerfasserIn  |0 (DE-588)1022346741  |0 (DE-627)716954850  |0 (DE-576)36517937X  |4 aut 
700 1 |a Müller, T.  |e VerfasserIn  |4 aut 
700 1 |a Giorgadze, K.  |e VerfasserIn  |0 (DE-588)128659328X  |0 (DE-627)1843118203  |4 aut 
700 1 |a Frei, Claudia  |e VerfasserIn  |0 (DE-588)1286593387  |0 (DE-627)1843118378  |4 aut 
700 1 |a Giese, Thomas  |d 1962-  |e VerfasserIn  |0 (DE-588)143133543  |0 (DE-627)704399075  |0 (DE-576)333724496  |4 aut 
700 1 |a Bergmann, Frank  |d 1972-  |e VerfasserIn  |0 (DE-588)124407900  |0 (DE-627)363326081  |0 (DE-576)294157840  |4 aut 
700 1 |a Schmidt, Jan  |d 1961-  |e VerfasserIn  |0 (DE-588)1022937995  |0 (DE-627)717335852  |0 (DE-576)366198017  |4 aut 
700 1 |a Werner, Jens  |d 1966-  |e VerfasserIn  |0 (DE-588)120690764  |0 (DE-627)704926717  |0 (DE-576)292340249  |4 aut 
700 1 |a Büchler, Markus W.  |d 1955-  |e VerfasserIn  |0 (DE-588)120893339  |0 (DE-627)080952526  |0 (DE-576)292434146  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Giese, Nathalia  |e VerfasserIn  |0 (DE-588)1033180955  |0 (DE-627)740120018  |0 (DE-576)380769123  |4 aut 
773 0 8 |i Enthalten in  |t Cancer immunology immunotherapy  |d Berlin : Springer, 1976  |g 59(2010), 9 vom: Juni, Seite 1389-1400  |h Online-Ressource  |w (DE-627)253390443  |w (DE-600)1458489-X  |w (DE-576)072283475  |x 1432-0851  |7 nnas  |a Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer 
773 1 8 |g volume:59  |g year:2010  |g number:9  |g month:06  |g pages:1389-1400  |g extent:12  |a Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer 
856 4 0 |u https://doi.org/10.1007/s00262-010-0870-9  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230419 
993 |a Article 
994 |a 2010 
998 |g 1033180955  |a Giese, Nathalia  |m 1033180955:Giese, Nathalia  |d 910000  |d 910200  |e 910000PG1033180955  |e 910200PG1033180955  |k 0/910000/  |k 1/910000/910200/  |p 12  |y j 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 11 
998 |g 120893339  |a Büchler, Markus W.  |m 120893339:Büchler, Markus W.  |d 910000  |d 910200  |e 910000PB120893339  |e 910200PB120893339  |k 0/910000/  |k 1/910000/910200/  |p 10 
998 |g 120690764  |a Werner, Jens  |m 120690764:Werner, Jens  |d 910000  |d 910200  |e 910000PW120690764  |e 910200PW120690764  |k 0/910000/  |k 1/910000/910200/  |p 9 
998 |g 1022937995  |a Schmidt, Jan  |m 1022937995:Schmidt, Jan  |d 910000  |d 910200  |e 910000PS1022937995  |e 910200PS1022937995  |k 0/910000/  |k 1/910000/910200/  |p 8 
998 |g 124407900  |a Bergmann, Frank  |m 124407900:Bergmann, Frank  |d 910000  |d 912000  |e 910000PB124407900  |e 912000PB124407900  |k 0/910000/  |k 1/910000/912000/  |p 7 
998 |g 143133543  |a Giese, Thomas  |m 143133543:Giese, Thomas  |d 910000  |d 911600  |e 910000PG143133543  |e 911600PG143133543  |k 0/910000/  |k 1/910000/911600/  |p 6 
998 |g 1286593387  |a Frei, Claudia  |m 1286593387:Frei, Claudia  |d 910000  |d 910100  |e 910000PF1286593387  |e 910100PF1286593387  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 128659328X  |a Giorgadze, K.  |m 128659328X:Giorgadze, K.  |d 910000  |d 910200  |e 910000PG128659328X  |e 910200PG128659328X  |k 0/910000/  |k 1/910000/910200/  |p 4 
998 |g 1022346741  |a Zörnig, Inka  |m 1022346741:Zörnig, Inka  |d 910000  |d 910100  |e 910000PZ1022346741  |e 910100PZ1022346741  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1033180734  |a Heller, Anette  |m 1033180734:Heller, Anette  |d 910000  |d 912000  |e 910000PH1033180734  |e 912000PH1033180734  |k 0/910000/  |k 1/910000/912000/  |p 1  |x j 
999 |a KXP-PPN1843116804  |e 4311105096 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer","title_sort":"Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer"}],"note":["Gesehen am 19.04.2023"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"display":"Heller, Anette","given":"Anette","role":"aut","family":"Heller"},{"family":"Zörnig","given":"Inka","role":"aut","display":"Zörnig, Inka"},{"family":"Müller","given":"T.","role":"aut","display":"Müller, T."},{"family":"Giorgadze","role":"aut","given":"K.","display":"Giorgadze, K."},{"display":"Frei, Claudia","role":"aut","given":"Claudia","family":"Frei"},{"family":"Giese","given":"Thomas","role":"aut","display":"Giese, Thomas"},{"family":"Bergmann","given":"Frank","role":"aut","display":"Bergmann, Frank"},{"family":"Schmidt","given":"Jan","role":"aut","display":"Schmidt, Jan"},{"family":"Werner","given":"Jens","role":"aut","display":"Werner, Jens"},{"role":"aut","given":"Markus W.","family":"Büchler","display":"Büchler, Markus W."},{"family":"Jäger","role":"aut","given":"Dirk","display":"Jäger, Dirk"},{"display":"Giese, Nathalia","given":"Nathalia","role":"aut","family":"Giese"}],"relHost":[{"origin":[{"dateIssuedDisp":"1976-","dateIssuedKey":"1976","publisherPlace":"Berlin ; Heidelberg","publisher":"Springer"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 15.05.2024","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 52.2003: Supplement"],"title":[{"subtitle":"CII","title_sort":"Cancer immunology immunotherapy","title":"Cancer immunology immunotherapy"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"253390443","disp":"Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancerCancer immunology immunotherapy","titleAlt":[{"title":"CII"}],"pubHistory":["1.1976 -"],"id":{"eki":["253390443"],"issn":["1432-0851"],"zdb":["1458489-X"]},"part":{"year":"2010","volume":"59","pages":"1389-1400","issue":"9","text":"59(2010), 9 vom: Juni, Seite 1389-1400","extent":"12"}}],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"01 June 2010"}],"recId":"1843116804","physDesc":[{"noteIll":"Illustrationen","extent":"12 S."}],"id":{"doi":["10.1007/s00262-010-0870-9"],"eki":["1843116804"]},"name":{"displayForm":["A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M.W. Buchler, D. Jaeger, N.A. Giese"]}} 
SRT |a HELLERANETIMMUNOGENI0120